Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation

Launched by LES LABORATOIRES DES MÉDICAMENTS STÉRILES · Feb 28, 2025

Keywords

ClinConnect Summary

Atrial fibrillation (AF) is the most common heart rhythm disorder with an estimated global prevalence of between 1 and 2%. It is a serious pathology that considerably increases morbidity and mortality. Thromboembolic events are a major complication .

Thus, effective anticoagulation is one of the major pillars of the management of atrial fibrillation. This anticoagulation was for a long time based on vitamin K antagonists (VKAs) which have proven their effectiveness in significantly reducing the risk of thromboembolic complications. However, VKAs have several drawbacks, mainly related to th...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female ≥ 18 years of age
• • Patients diagnosed with AF;
• • Written informed consent obtained prior to participation in the study.
• Exclusion Criteria:
• * Patients with at least one of the following criteria will not be included in the trial:
• • History of hypersensitivity to study drugs or drugs with a similar chemical structure.
• • Patients receiving combination therapy of P-glycoprotein inhibitors or inducers such as itraconazole, ketoconazole, voriconazole, posaconazole, ritonavir, rifampicin, phenytoin, phenobarbital, and carbamazepine, within 14 days prior to taking apixaban
• • Pregnant women
• • Breastfeeding
• • Patients Enrolled in Other Clinical Studies
• • Patients who refuse to sign consent.